Propanc Biopharma Plans Strategic Acquisition of Undervalued Digital Asset Firms

According to PANews, Propanc Biopharma (NASDAQ: PPCB) has announced a strategic initiative to acquire digital asset management (DAT) companies that are currently trading below their market-to-net asset value (MNAV). The company's leadership views this acquisition strategy as an opportunity to strengthen Propanc's balance sheet, diversify its assets, and create long-term value for shareholders. These DAT companies typically hold significant amounts of mainstream digital assets like Bitcoin and Ethereum on their balance sheets. Propanc's board and executive team are actively evaluating potential acquisition targets and developing a due diligence framework to assess balance sheet strength, digital asset holdings, and operational synergies.